Targeting cancer cells - More pathways, more inhibitors, more trials

MedGenMed Medscape General Medicine

Volumn 6, Issue 4, 2004, Pages

  Mariani, Sara M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; AEW 541; ANTIESTROGEN; ANTINEOPLASTIC AGENT; BORTEZOMIB; BUTYRIC ACID DERIVATIVE; CAMPTOTHECIN; CISPLATIN; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FR 901228; HISTONE ACETYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELPHALAN; MS 277; PDX 101; PHOSPHOTRANSFERASE INHIBITOR; PIVALOYLOXYMETHYL BUTYRATE; PREDNISONE; PROTEIN MLH1; RAPAMYCIN; SOMATOMEDIN RECEPTOR; TEMSIROLIMUS; TENIPOSIDE; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VINCRISTINE; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER RESEARCH; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; GENE EXPRESSION; HUMAN; IN VITRO STUDY; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; PERIPHERAL NEUROPATHY; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR VASCULARIZATION;

EID: 24644507378     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer. 2003;107:873-877.
2. LeRoith D, Helman L. The new kid on the block(ade) of the IGF-1 receptor. Cancer Cell. 2004;5:201-202.
3. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology. 2002;63:317-332.
4. Hofmann F. Selective IGF-IR kinase inhibitors as promising novel anti-cancer agents. Program and abstracts of the 9th Annual Drug Discovery Technology World Congress; August 8-13, 2004; Boston, Massachusetts.
5. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346-1353.
6. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene. 2004;23:3151-3171.
7. Gibbons JJ. The mTOR pathway as a target for cancer therapy - the effect of CCI-779. Program and abstracts of the 9th Annual Drug Discovery Technology World Congress; August 8-13, 2004; Boston, Massachusetts.
8. Sawyers CL. Will mTOR inhibitors make it as cancer drugs? Cancer Cell. 2003;4:343-348.
9. Houghton PJ, Huang S. mTOR as a target for cancer therapy. Curr Top Microbiol Immunol. 2004;279:339-359.
10. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer. 2001;8:249-258.
11. Frost P, Moatomed F, Hoang B, et al. In vivo anti-tumor effects of the mTOR inhibitor, CCI-779, against human multiple myeloma cells in a xenograft model. Blood. 2004 Aug 10 [Epub ahead of print].
12. Panwalkar A, Verstovsek S, Giles FJ. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer. 2004;100:657-666.
13. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4:349-360.
14. Richardson PG, Hideshima T, Mitsiades C, Anderson K. Proteasome inhibition in hematologic malignancies. Ann Med. 2004;36:304-314.
15. Park DJ, Lenz HJ. The role of proteasome inhibitors in solid tumors. Ann Med. 2004;36:296-303.
16. Cooper M. Targeting the ubiquitin proteasome pathway in hematologic malignancies. Program and abstracts of the 9th Annual Drug Discovery Technology World Congress; August 8-13, 2004; Boston, Massachusetts.
17. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
18. O'Connor OA. The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas. Curr Treat Options Oncol. 2004;5:269-281.
19. Legube G, Trouche D. Regulating histone acetyltransferases and deacetylases. EMBO Rep. 2003;4:944-947.
20. Marks PA, Miller T, Richon VM. Histone deacetylases. Curr Opin Pharmacol. 2003;3:344-351.
21. Carrozza MJ, Utley RT, Workman JL, Cote J. The diverse functions of histone acetyltransferase complexes. Trends Genet. 2003;19:321-329.
22. Carey N. Translating HDAC inhibitors into the clinic. Program and abstracts of the 9th Annual Drug Discovery Technology World Congress; August 8-13, 2004; Boston, Massachusetts.
23. Rosato RR, Grant S. Histone deacetylase inhibitors in clinical development. Expert Opin Investig Drugs. 2004;13:21-38.
24. Vigushin DM, Coombes RC. Targeted histone deacetylase inhibition for cancer therapy. Curr Cancer Drug Targets. 2004;4:205-218.
25. Crane R, Gadea B, Littlepage L, Wu H, Ruderman JV. Aurora A, meiosis and mitosis. Biol Cell. 2004;96:215-229.
26. Meraldi P, Honda R, Nigg EA. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev. 2004;14:29-36.
27. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev. 2003;22:451-464.
28. Mortlock AA. Novel inhibitors of aurora kinases. Program and abstracts of the 9th Annual World Congress Drug Discovery Technology; August 8-13, 2004; Boston, Massachusetts.
29. Hauf S, Cole RW, LaTerra S, et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol. 2003;161:281-294.
30. Ditchfield C, Johnson VL, Tighe A, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol. 2003;161:267-280.
31. Sausville EA. Aurora kinases dawn as cancer drug targets. Nat Med. 2004;10:234-235.
32. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med. 2004;10:262-267.